Filing Details

Accession Number:
0001601830-24-000077
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-06-07 16:01:53
Reporting Period:
2024-06-05
Accepted Time:
2024-06-07 16:01:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1601830 Recursion Pharmaceuticals Inc. RXRX Biological Products, (No Disgnostic Substances) (2836) 464099738
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1856369 Christopher Gibson C/O Recursion Pharmaceuticals
41 S. Rio Grande Street
Salt Lake City UT 84101
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2024-06-05 25,000 $0.00 833,738 No 4 C Direct
Class A Common Stock Disposition 2024-06-05 25,000 $0.00 808,738 No 4 G Direct
Class A Common Stock Disposition 2024-06-05 50,000 $8.42 758,738 No 4 S Direct
Class A Common Stock Disposition 2024-06-06 50,000 $9.00 708,738 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 G Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Class B Common Stock Disposition 2024-06-05 25,000 $0.00 25,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
6,401,700 No 4 C Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Class A Common Stock Class B Common Stock $0.00 0 486,000 Indirect
Class A Common Stock Class B Common Stock $0.00 0 388,000 Indirect
Class A Common Stock Class B Common Stock $0.00 0 67,875 Indirect
Class A Common Stock Stock Option (Right to Buy) $8.55 2033-02-01 0 813,600 Direct
Class A Common Stock Stock Option (Right to Buy) $2.48 2030-12-30 0 312,500 Direct
Class A Common Stock Stock Option (Right to Buy) $11.40 2032-02-04 0 399,002 Direct
Class A Common Stock Stock Option (Right to Buy) $11.40 2022-02-04 2032-02-04 0 5,436 Direct
Class A Common Stock Stock Option (Right to Buy) $10.09 2034-02-09 0 666,898 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
0 486,000 Indirect
0 388,000 Indirect
0 67,875 Indirect
2033-02-01 0 813,600 Direct
2030-12-30 0 312,500 Direct
2032-02-04 0 399,002 Direct
2032-02-04 0 5,436 Direct
2034-02-09 0 666,898 Direct
Footnotes
  1. Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a bona-fide gift of shares by the Reporting Person.
  2. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023.
  3. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
  4. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
  5. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
  6. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
  7. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
  8. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
  9. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
  10. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.